ASMI disappointed on S3 advertising recommendation

ASMI says that the Expert Panel report on the regulatory framework for medicines and medical devices falls short in its recommendation to retain restrictions on the advertising of S3 medicines. ASMI’s Executive Director, Deon Schoombie, welcomed the Panel’s recommendations on the scheduling framework for non-prescription medicines, saying that suggested changes are long overdue. “However, while